The Rutinib product family presented on this website consists of three products associated with the active ingredient ruxolitinib.
Rutinib Cream
Active ingredient: Ruxolitinib
Formulation: Cream
Route: Topical
Therapeutic context: Dermatologic treatment
Topical ruxolitinib has established evidence and regulatory uses in atopic dermatitis and nonsegmental vitiligo.
Rutinib 5 mg
Active ingredient: Ruxolitinib
Strength: 5 mg
Formulation: Oral
Route: Oral
Therapeutic context: Systemic treatment
Ruxotor 10 mg
Active ingredient: Ruxolitinib
Strength: 10 mg
Formulation: Oral
Route: Oral
Therapeutic context: Systemic treatment
Product Comparison
| Product | Ingredient | Route | Strength | Treatment Context |
|---|---|---|---|---|
| Rutinib Cream | Ruxolitinib | Topical | Cream formulation | Dermatologic |
| Rutinib 5 mg | Ruxolitinib | Oral | 5 mg | Systemic |
| Ruxotor 10 mg | Ruxolitinib | Oral | 10 mg | Systemic |
Reference Products
The established U.S. topical reference product is OPZELURA, while JAKAFI is the established U.S. oral ruxolitinib product.
Important
The three Rutinib products are related through ruxolitinib but are not automatically interchangeable.